// App-Quantinova.ai

4851 : Second generation 2,3-dihydroimidazo[1,2-c]quinazoline PI3K inhibitors: development of BAY 1082439, a novel balanced PI3Ka / PI3Ka inhibitor

Researchers

Presenter

  • William J. Scott

Principal Investigators

  • Ningshu Liu

  • Andreas Hagebarth

  • Manfred Mowes

  • Ursula Monning

  • Ulf Bomer

  • Dominik Mumberg

  • Franz von Nussbaum

  • Michael Brands

  • Julien Lafranc

Medical Centers

  • Bayer HealthCare Pharmaceuticals, Whippany, NJ

  • Bayer Healthcare Pharmaceuticals, Inc., Berlin, Germany

Locations

  • United States

  • Germany

Companies

  • Bayer HealthCare Pha

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Drug/Treatment

  • BAY-1082439

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved